Ray Saumitra, Nair Tiny, Sawhney Jps, Rosman Azhari, Reyes Eugene, Go Loewe, Sukonthasarn Apichard, Ariyachaipanich Aekarach, Hung Phạm Manh, Chaudhari Harshal, Malhi Harshveer Singh
Department of Cardiology, AMRI Hospital (S), West Bengal, Kolkata, India.
Department of Cardiology, PRS Hospital, Trivandrum, Kerala, India.
Curr Med Res Opin. 2023 Dec;39(12):1671-1683. doi: 10.1080/03007995.2023.2256218. Epub 2023 Sep 11.
This Delphi method of consensus was designed to develop scientific statements for β-blockers in the continuum of cardiovascular diseases with a special focus on the role of bisoprolol.
Eleven experienced cardiologists from across the Asia-Pacific countries participated in two rounds of the survey. In the first round, experts were asked to rate agreement/disagreement with 35 statements across seven domains regarding the use of β-blockers for treating hypertension, heart failure, coronary artery diseases, co-morbidities, as well as their safety profile, usage pattern, and pharmacokinetic variability. A consensus for a statement could be reached with >70% agreement.
Except for seven statements, all attained consensus in the first round. In the second round that was conducted virtually, the experts re-appraised their ratings for the seven statements along with a critical appraisal of two additional statements that were suggested by experts in the preceding round. At the end of the second round, the final version included 36 statements (34 original statements, two statements suggested by experts, and the omission of one statement that did not attain consensus). The final version of statements in the second round was disseminated among experts for their approval followed by manuscript development.
Attainment of consensus for almost all statements reconfirms the clinical benefits of β-blockers, particularly β1-selective blockers for the entire spectrum of cardiovascular diseases.
本德尔菲共识方法旨在针对心血管疾病连续过程中的β受体阻滞剂制定科学声明，特别关注比索洛尔的作用。
来自亚太国家的11位经验丰富的心脏病专家参与了两轮调查。在第一轮中，要求专家对关于使用β受体阻滞剂治疗高血压、心力衰竭、冠状动脉疾病、合并症以及其安全性概况、使用模式和药代动力学变异性的七个领域的35项声明进行同意/不同意评分。声明达成共识的标准是同意率>70%。
除七项声明外，所有声明在第一轮中均达成共识。在虚拟进行的第二轮中，专家们重新评估了他们对这七项声明的评分，并对前一轮专家提出的另外两项声明进行了批判性评估。在第二轮结束时，最终版本包括36项声明（34项原始声明、专家建议的两项声明以及一项未达成共识的声明被遗漏）。第二轮声明的最终版本在专家中传播以供批准，随后进行稿件撰写。
几乎所有声明达成共识再次证实了β受体阻滞剂，特别是β1选择性阻滞剂对整个心血管疾病谱的临床益处。
